Intronic CYP46 polymorphism along with ApoE genotype in sporadic Alzheimer Disease: From risk factors to disease modulators

Neurobiology of Aging

Volumn 25, Issue 6, 2004, Pages 747-751

  Borroni, Barbara ^a   Archetti, Silvana ^a   Agosti, Chiara ^a   Akkawi, Nabil ^a   Brambilla, Cristina ^a   Caimi, Luigi ^a   Caltagirone, Carlo ^b   Di Luca, Monica ^c   Padovani, Alessandro ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer Disease; ApoE; CYP46; Rate of cognitive decline; Risk factors

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME P450; CYTOCHROME P450 46; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DNA POLYMORPHISM; EVALUATION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CYSTEINE; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRONS; MALE; MENTAL STATUS SCHEDULE; ODDS RATIO; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; STEROID HYDROXYLASES; TIME FACTORS; TYROSINE;

EID: 2542523048     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2003.08.004     Document Type: Article

References (24)

1. Bogdanovic N., Bretillon L., Lund E.G., Diczfalusy U., Lannfelt L., Winblad B., et al. On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. Neurosci. Lett. 314:2001;45-48
2. Borroni B., Colciaghi F., Lenzi G.L., Caimi L., Cattabeni F., Di Luca M., Padovani A. High cholesterol affects platelet APP processing in controls and in AD patients. Neurobiol. Aging. 24(5):2003;631-636
3. Borroni B., Pettenati C., Bordonali T., Akkawi N., Di Luca M., Padovani A. Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer Disease. Neurosci. Lett. 343:2003;213-215
4. Chapman P.F., Falinska A.M., Knevett S.G., Ramsay M.F. Genes, models and Alzheimer's disease. Trends Genet. 17:2001;254-261
5. Desai P., DeKosky S.T., Kamboh M.I. Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease. Neurosci. Lett. 328:2002;9-12
6. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 98:2001;5856-5861
7. Fassbender K., Stroick M., Bertsch T., Ragoschke A., Kuehl S., Walter S., et al. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology. 59:2002;1257-1258
8. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet. 356:2000;1627-1631
9. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., et al. Apolipoprotein E epsilon 4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann. Intern Med. 137:2002;149-155
10. Kolsch H., Lutjohann D., Ludwig M., Schulte A., Ptok U., Jessen F., et al. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol. Psychiatry. 7:2002;899-902
11. Lund E.G., Guileyardo J.M., Russell D.W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. USA. 13:1999;7238-7243
12. Marx J. Alzheimer's disease. Bad for heart, bad for the mind? Science. 294:2001;508-509
13. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34:1984;939-944
14. Michikawa M., Fan Q.W., Isobe I., Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 74:2000;1008-1016
15. Michikawa M. The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol. Mol. Neurobiol. 27:2003;1-12
16. Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R., et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36:2002;27-32
17. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 60:2003;29-35
18. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol. Med. 9:2003;94-101
19. Puglielli L., Tanzi R.E., Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6:2003;345-351
20. Refolo L.M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7:2000;321-331
21. Refolo L.M., Pappolla M.A., LaFrancois J., Malester B., Schmidt S.D., Thomas-Bryant T., et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol. Dis. 8:2001;890-899
22. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472
23. Vega G.L., Weiner M.F., Lipton A.M., Von Bergmann K., Lutjohann D., Moore C., et al. Reduction in levels of 24S-hydroxycholesterol by statin treatment in patients with Alzheimer disease. Arch. Neurol. 60:2003;510-515
24. Wolozin B. CYP46 (24-cholesterol hydroxylase). A genetic risk factor for Alzheimer disease. Arch. Neurol. 60:2003;16-18